Literature DB >> 24237646

Gemcitabine-induced thrombotic microangiopathy.

J Richmond1, P Gilbar, E Abro.   

Abstract

Thrombotic microangiopathy (TMA) is a microvascular occlusive disorder characterised by platelet aggregation, thrombocytopenia and end-organ damage. It is commonly idiopathic, although several drug classes, including cytotoxic chemotherapy, have been implicated. Several of cases of gemcitabine-induced TMA have been documented with incidence likely to increase with the escalating use of gemcitabine. We report the cases of two patients who developed TMA while on gemcitabine chemotherapy.
© 2013 The Authors; Internal Medicine Journal © 2013 Royal Australasian College of Physicians.

Entities:  

Keywords:  chemotherapy; gemcitabine; thrombotic microangiopathy

Mesh:

Substances:

Year:  2013        PMID: 24237646     DOI: 10.1111/imj.12261

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  8 in total

1.  Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.

Authors:  Adarsh Das; Andrew Dean; Tim Clay
Journal:  BMJ Case Rep       Date:  2019-04-08

2.  Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Authors:  Florence Daviet; Franck Rouby; Pascale Poullin; Julie Moussi-Francès; Marion Sallée; Stéphane Burtey; Julien Mancini; Florence Duffaud; Renaud Sabatier; Bertrand Pourroy; Aurélie Grandvuillemin; Steven Grange; Véronique Frémeaux-Bacchi; Paul Coppo; Joëlle Micallef; Noémie Jourde-Chiche
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

3.  ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.

Authors:  Peter G Bittar; Myles S Nickolich; Oluwatoyosi A Onwuemene
Journal:  J Clin Apher       Date:  2017-09-23       Impact factor: 2.821

4.  Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.

Authors:  Maureen Assayag; Philippe Rouvier; Marion Gauthier; Ghania Costel; Philippe Cluzel; Lucile Mercadal; Gilbert Deray; Corinne Isnard Bagnis
Journal:  BMC Cancer       Date:  2017-11-16       Impact factor: 4.430

5.  Gemcitabine-Induced Hemolytic Uremic Syndrome in Lung Cancer: A Case Report.

Authors:  Prashant Ahlawat; Monica Gupta; Prateek Upadhyay; Shivani Gupta; Amanjot Kaur
Journal:  Cureus       Date:  2022-01-04

6.  Gemcitabine-Induced Thrombotic Microangiopathy Managed Conservatively in a Patient of Breast Cancer.

Authors:  Ghulam Mujtaba Ghumman; Huda Fatima; Tyler L Johnston; Rachel Leis; Vinod Khatri
Journal:  Cureus       Date:  2022-08-26

7.  IgA-Dominant Glomerulopathy and Thrombotic Microangiopathy After Chemotherapy.

Authors:  Zeljko Dvanajscak; Bethany E Karl; Amber P Sanchez; Vighnesh Walavalkar
Journal:  Kidney Int Rep       Date:  2017-11-03

Review 8.  Management of acute kidney injury in gastrointestinal tumor: An overview.

Authors:  Yi-Qi Su; Yi-Yi Yu; Bo Shen; Feng Yang; Yu-Xin Nie
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.